LUNAR-COV19 utilizes Arcturus’ self-transcribing and replicating mRNA (STARR™) technology and the Company’s LUNAR® lipid-mediated delivery to produce an extraordinarily low dose, potential single shot COVID-19 vaccine. The manufacture
Junshi Biosciences, a Chinese biopharmaceutical company, is working to discover therapies to combat Covid-19 from the starting of the outbreak. The company has designed multiple neutralising antibodies and
Novartis announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the approval of Enerzair® Breezhaler® (QVM149;
The Government of Canada has granted the funds under Innovation, Science and Economic Development’s (ISED) Strategic Innovation Fund (SIF) to support the discovery of antibodies for use in
Under the terms of the agreement, the companies plan to establish manufacturing suites at Lonza’s facilities in the United States and Switzerland for the manufacture of mRNA-1273 at
The collaboration will allow to develop and distribute the university’s potential recombinant adenovirus vaccine for the prevention of COVID-19 infection from SARS-CoV-2. The potential vaccine, dubbed ChAdOx1 nCoV-19,
The collaboration commits joint investment to accelerate rapid scale-up of segregated manufacturing capacity over the coming months to support dedicated production of Johnson & Johnson’s investigational vaccine candidate.
The open-label and phase 3 SIMPLE trial has assessed five-day and 10-day dosing durations of the investigational antiviral remdesivir in hospitalised patients with severe manifestations of COVID-19 disease.
The partnership will focus on utilizing Quotient’s integrated service portfolio to support the rapid development of CytoAgents’ lead COVID-19 drug candidate, GP1681, for Phase I and II in
The CAN-COVID study will assess the efficacy of using canakinumab for the treatment of a type of severe immune overreaction known as cytokine release syndrome (CRS) in people
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.